Haemonetics is trading at $114.12, up 12.2%, with the reason for the gain unconfirmed. - Shares compare with the October 7 close of $101.71. - Available news search identified no clear company-specific catalyst for October 8; the latest investor-relations releases list second-quarter fiscal 2027 results for November 5, not an October 8 announcement. - The broader market is weaker in pre-market and does not explain the gain; an earlier report also described the rise as lacking a confirmed catalyst.